State Ledger
Company profile

ArriVent BioPharma, Inc. CIK 1868279

Ticker
AVBP (Nasdaq)
Industry
Pharmaceutical Preparations
Headquarters
Newtown Square, PA 19073-3269
Fiscal year end
2025 (FY)
Market Data
Close
$16.46
Change
-$0.28
Change %
-1.64%
Volume
98,096

AVBP · trading date Oct 12, 2026 · previous close $16.73 · source: Alpaca (IEX feed, not consolidated full-market data).

Key Financials
Revenue
—
Net income
-$166.31M
Total assets
$333.17M
Total liabilities
$25.95M
Stockholders' equity
$307.22M
Cash & equivalents
$45.54M
Operating income
-$177.53M
Operating cash flow
-$160.59M
Capital expenditures
—

Fiscal year 2025, via 10-K filed 2026-03-05. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.

Financial Performance
Operating margin
—
Net margin
—
Free cash flow
—
Free cash flow margin
—
Liabilities / assets
7.8%
Equity / assets
92.2%
CapEx / revenue
—
Operating cash flow / net income
0.97×

Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.

Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2025 — -$166.31M $333.17M $25.95M $307.22M
2024 — -$80.49M $274.94M $17.29M $257.65M
2023 — -$69.33M $163.10M $11.80M -$153.19M
Company Details
SIC code
2834
State of incorporation
DE
Active filer
Yes
Most recent SEC filing
Form 10-Q
2026-08-12
Financials filed via
Form 10-K
filed 2026-03-05

"Most recent SEC filing" may differ from the filing used for the financial figures above.

Location
Newtown Square, PA 19073-3269
18 CAMPUS BLVD.
Data & Methodology

SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:53 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.

← Back to Pennsylvania — Public Companies